Pacira dinged on Exparel "disruptions"

Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) fell $14.70 (14%) to $91.11 on Thursday as investors digested comments on the company's earnings call related to a previously announced September warning letter from FDA about off-label marketing of pain drug Exparel. The bupivacaine liposome extended-release injectable suspension is approved for postoperative pain management.

Barclays analyst Douglas Tsao asked whether FDA's letter had caused "any impact in terms of accounts." ...